Commercial With nearly a quarter billion in Q1, J&J targets $100B revenue in 2026 pharminent April 14, 2026
Commercial With oral obesity race underway, all eyes are on Lilly’s Foundayo launch pharminent April 10, 2026
Commercial Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk pharminent April 9, 2026
Commercial Approvals in Hand, Lilly and Novo Obesity Pills Will Battle It Out on Hairline Differences pharminent April 2, 2026
